



an Open Access Journal by MDPI

Targeted Therapy for Breast Cancer: Focus on the Apoptosis Pathway

Guest Editors:

Dr. Jangsoon Lee

Department of Breast Medical
Oncology, Division of Cancer
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX, USA

Dr. Bora Lim

Dan L Duncan Comprehensive
Cancer Center, Baylor College of
Medicine, Houston, TX 77030,
USA

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editors

Apoptosis is a type of programmed cell death. There are two major types of apoptosis pathway: 1) intrinsic pathways that are initiated by intracellular pathways such as DNA damage, ER stress, hypoxia, and metabolic stress, and 2) extrinsic pathways that are initiated by death receptor activation (TRAILR and FAS) from a signal outside cells. Apoptosis resistance is a hallmark of human cancer, and apoptosis regulators have been targeted for drug development regarding cancer treatment. Breast cancer is a heterogeneous disease that often develops resistance toward standard care treatments, such as hormone therapy, anti-HER2 therapy, chemotherapy, or radiotherapy. It has been reported that anti-apoptotic BCL-2 family members are frequently found to be up-regulated in breast cancer and correlate with poor prognosis. In this issue, we welcome original research and review articles that discuss the discovery of novel mechanisms of apoptosis, potential drug targets, biomarkers, and new inhibitors that may overcome apoptosis resistance and provide effective therapeutic approaches for use in the treatment of breast cancer.



mdpi.com/si/102378

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)